Zhengyu Jiang

Zhengyu Jiang is a prominent inventor based in Nanjing, China. He has made significant contributions to the field of biochemistry, particularly in the development of protein-protein interaction inhibitors. With a total of five patents to his name, Jiang's work focuses on innovative solutions for treating acute leukemia and related diseases.

Latest Patents

One of Jiang's latest patents is an aniline-based WDR5 protein-protein interaction inhibitor. This patent discloses a compound that selectively inhibits the proliferation of leukemia cells by acting on the WDR5 protein and its interacting proteins, including MLL. The inhibitor also affects the methylation of H3K4 and the expression of downstream Hox/Meis-1 genes at the cellular level. Additionally, Jiang has developed a hydrogen peroxide-responsive KEAP1-NRF2 PPI inhibitor prodrug. This prodrug is designed to achieve targeted activation of Nrf2 and enhance therapeutic efficacy in the body. It represents a novel approach to ROS activation-ROS clearance therapy and is expected to be clinically applicable due to its druggability and high targeting ability.

Career Highlights

Jiang's career is marked by his dedication to advancing pharmaceutical research. His work at China Pharmaceutical University has positioned him as a key figure in the development of innovative therapeutic agents. His research has the potential to significantly impact the treatment of various diseases, particularly acute leukemia.

Collaborations

Jiang collaborates with notable colleagues, including Qidong You and Xiaoli Xu. Their combined expertise enhances the research and development of new therapeutic strategies.

Conclusion

Zhengyu Jiang's contributions to the field of protein-protein interaction inhibitors demonstrate his commitment to innovation in pharmaceutical research. His patents reflect a deep understanding of biochemistry and a drive to improve treatment options for serious diseases.

This text is generated by artificial intelligence and may not be accurate.